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HE POPULAR MEDIA PLAY A CRUCIAL ROLE IN 
communicating  information  about  health 
treatments. By informing the public about new 
research  findings,  they  can  affect  how  medical  treat-
ments are perceived1 and, in so doing, influence their 
use.2  Although  some  medical  reporting  is  driven  
by public interest, many stories are prompted by com-
panies, universities and research groups who are pro-
moting their work and hope to get favourable coverage 
of it from major media outlets.3–5 A recent analysis by 
public  relations  specialists  argues  that  the  shift  from 
traditional advertising to public relations is one of the 
most dramatic changes in the  marketing  field in dec-
ades and has come about because of the perceived supe-
riority of this approach.3 
  Most  recent  studies  of  media  coverage  of  medical 
treatments have found that many stories about pharma-
ceuticals lack complete information, particularly details 
on the quality of evidence and on the reported benefits, 
harms and costs of treatments.6–7 Research in this area  
in  Canada  has  led  to  recent  calls  for  more  direct  and 
honest reporting of the results of research.3,8,9 In the last 
three  years,  three  different  services  —  Media  Doctor 
Australia  (www.mediadoctor.org.au/),  Media  Doctor 
Canada  (www.mediadoctor.ca)  and  Health  News  Re-
views (www.healthnewsreview.org) in the United States 
— have monitored hundreds of health treatment stories 
using similar criteria, posting results to their websites.  
  Media  Doctor  Australia,  with  input  from  medical 
media  researchers  in  Canada  and  the  United  States, 
developed 10 criteria with which to analyze media stor-
ies  about  treatments.10  Our  group,  Media  Doctor 
Canada, adapted these into a similar tool, dropping a 
criterion  about  the  presence  or  absence  of  press  re-
leases and adding one about the quantification of harms 
from treatments. Table 1 shows the 10 criteria that we 
ultimately used. 
  We  assembled  a  team  of  12  reviewers  with  back-
grounds  in  clinical  epidemiology,  clinical  medicine, 
evidence-based medicine and media studies from per-
sonal contacts and people who had been involved in an 
earlier study of medical media reporting in Canada.6,11 
Over  an  18-month  period  between  31  May  2005  and  
1 November 2006, Media Doctor Canada analyzed 87 
unique stories dealing with treatments that appeared in 
10 major English-language daily newspapers, a medical 
news service directed toward health professionals, and 
two  web-based  news  services  that  are  linked  to  two 
major  broadcasters  in  Canada  (CBC  and  CTV).  Our 
method  of  evaluating  stories  followed  the  procedure 
used in Australia: Each story was rated Satisfactory or 
Not Satisfactory for each of the 10 criteria by two re-
viewers, and any disagreements were resolved by con-
sensus. We felt that media coverage may be different for 
stories dealing with pharmaceuticals versus other forms 
of treatment, so we examined stories in these two cate-
gories separately. 
  Table 2 shows the percentage of Satisfactory scores 
for  each  of  the  10  different  rating  criteria  for  all  87 
stories  about  pharmaceuticals  and  other  forms  of 
treatment. Nearly all stories dealing with pharmaceuti-
cals  and  other  treatments  were  rated  Satisfactory  on 
two criteria: Novelty of Treatment (93.8%) and Disease-
Mongering (89.7%). This is to say that the stories did 
not exaggerate or misconstrue the novelty of the treat-
ment (saying something was new when it was not) or
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Table 1:  Media Doctor Canada rating instrument for assessing the quality of news stories about medical treatments 
Dimension  Not Satisfactory  Satisfactory 
1.  Availability of  
     treatment 
No mention of availability of treatment in Canada  Accurate information on availability of treatment in  
Canada (both approval and provincial drug plan status) 
2.  Cost of treatment  No mention of cost, or cost downplayed as an issue, 
or 
Mention of cost only; no comparative information 
Mention of comparative cost and comments on  
cost-effectiveness 
3.  Disease-mongering  Risk factors (e.g., bone mineral density, cholesterol) 
framed as a disease, or 
No mention (or else misrepresentation) of natural 
history of disease, or 
Exaggeration of prevalence or incidence, or 
Medicalization of normal human variation 
No obvious elements of disease-mongering 
4.  Evidence  No mention of the nature of clinical evidence,  
especially RCTs, or 
Mention of the nature of the evidence but  
inappropriate interpretation or discussion  
Where relevant, mention of strength of evidence and  
correct interpretation 
5.  Harms of treatment  No mention of harms, or discounting of potential 
harms 
Balanced information about harms (frequency or  
seriousness) 
6.  Novelty of treatment  No mention (or else inaccurate representation)  
of whether treatment is genuinely new or just a  
re-formulation of an existing treatment, or another  
member of a well-established drug class 
Accurate information on novelty (or lack thereof) 
7.  Quantification of  
     benefits of treatment 
No quantitative estimate of benefit, or 
Quantitative estimate in relative frame only 
Estimate in both absolute and relative frames, or  
absolute frame only, or rates with and without treatment 
8. Quantification of harms 
    of treatment 
No quantification of harms rates an “NS”   Even some quantification of harm rates an “S” 
9.  Sources of information  No mention of sources or possible conflict of  
interest (COI) 
No attempt at independent corroboration 
Detail on information sources and their potential COI, 
reporting on independent source (a source with no  
potential financial COI), or mention of unsuccessful at-
tempt to obtain corroboration 
10. Treatment options  No mention of alternatives or their comparative  
performance 
Mention of appropriate alternatives and comparative 
information  
 
misrepresent the natural history of the disease (disease-
mongering). For all other criteria, fewer than half the 
stories  in  either  category  (pharmaceuticals  or  other 
therapies)  were  rated  Satisfactory.  The  largest  differ-
ence in the rate of Satisfactory scores between the two 
categories  was  for  Harms  of  Treatment:  49.2%  for 
pharmaceutical stories  versus 30.4% for stories about 
other treatments.  
  Our  results  were  consistent  with  those  reported  by 
Media  Doctor  Australia,  which  also  found  the  highest 
percentage of Satisfactory scores for Novelty of Treatment 
and Disease-Mongering.10 In addition, the lowest-scoring 
criterion in the Australian study was Costs of Treatment, 
which similarly ranked near the bottom in our study.  
  Despite  the consistency  between  these  two studies, 
there are a  few  possible  weaknesses to our approach. 
Although we trained our reviewers to apply the different 
criteria consistently, we recognize that there may have 
been  individual  biases  that  affected  the  scoring.  Fur-
thermore, we may have missed stories during our daily 
screening and selection, particularly because we looked 
only at stories from the largest English-language Cana-
dian newspapers and two broadcast news agencies. The 
quality of stories appearing in other media, especially 
small  media  outlets  where  there  are  no  journalists 
trained in health reporting, may be different. 
  Some journalists may consider our 10-criteria rating 
system  to  be  difficult  to  implement,  but  none  who 
communicated  to  us  about  our  evaluations  of  their 
stories raised this concern, and we have had many fa-
vourable reviews of our site.8 We recognize that many 
elements that go into making a “good” story from the ANALYSIS AND COMMENT                                                                                                            CASSELS AND LEXCHIN 
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Table 2: Ranking and percentage of “Satisfactory” scores on assessment criteria 
“Satisfactory” scores, %   
Rank   Criterion 
All stories  
(n = 87) 
Stories about pharmaceutical 
treatments (n = 64) 
Stories about “other 
treatments” (n = 23) 
1  Novelty of treatment  93.8  93.1  95.7 
2  Disease-mongering  89.7  89.1  91.3 
3  Availability of treatment  62.2  66.7  50.0 
4  Harms of treatment  44.2  49.2  30.4 
5  Treatment options  43.4  41.0  50.0 
6  Evidence  38.8  40.3  34.8 
7  Quantification of benefits of treatment  31.3  32.3  28.6 
8  Sources of information  25.0  21.0  36.4 
9  Cost of treatment  20.0  20.8  18.2 
10  Quantification of harms of treatment  8.2  8.0  8.7 
 
point of view of journalists may not have been consid-
ered,  but  do  not  believe  that  these  preclude  accurate 
and informed reporting. Similarly, there are arguments 
that short news stories cannot accommodate all of the 
criteria  we  measure.  However,  this  assertion  has  not 
been  supported  by  previous  work  in  which  we  have 
shown that there are few significant differences in the 
overall  quality  between  short  news  briefs  and  longer 
stories.11  
  The quality and comprehensiveness of the coverage 
of health technologies by the lay media is an important 
topic to study.1,12 Although journalism outlets strive13 to 
do a competent job while juggling competing interests, 
there  are  few  mechanisms  by  which  to  provide  them 
with  feedback  on  the  quality  of  their  coverage.  Since 
there  is  evidence  that  providing  timely  feedback  of 
performance data can improve practice standards,6,14,15 
auditing or monitoring the quality of health reporting in 
the lay press and feeding reviews back to news outlets 
may improve the informative value of these stories.  
   An obvious question then to ask is, Has Media Doc-
tor Canada made a difference in the quality of Canadian 
medical  reporting?  We  have  recorded  more  than 
59,000  unique  hits  on  our  site,  but  because  they  are 
anonymous we have no concrete evidence as to whether 
we are in fact contributing to the education of journal-
ists. In the future, we intend to continue to build our 
database of articles, to send scores back to the editors 
and journalists whose stories we assess, to broaden and 
refine the scoring instruments and to periodically sys-
tematically  analyze  the  collected  data  to  see  if  there 
have been any changes to the averages of the scoring 
criteria. One measure of success could be a finding of 
better  reporting  of  the  criteria  where  journalists  are 
currently missing the  mark, such as Quantification  of 
Harms of Treatment. If this were coupled with focus-
group  interviews  with  journalists  indicating  that  our 
site had a positive impact on their reporting, we could 
be confident that our endeavour was having a positive 
effect.  
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